Fertility and Sterility
Volume 94, Issue 6 , Pages 2202-2207 , November 2010

Serum antimüllerian hormone concentrations on day 3 of the in vitro fertilization stimulation cycle are predictive of the fertilization, implantation, and pregnancy in polycystic ovary syndrome patients undergoing assisted reproduction

  • Cemil Kaya, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University, Ankara, Turkey
    • Corresponding Author InformationReprint requests: Cemil Kaya, M.D., University Hospital, Department of Obstetrics and Gynecology, Ufuk University, Balgat, 312 Ankara, Turkey (FAX: + 90-312-2851158).
    • ,
  • Recai Pabuccu, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Faculty of Medicine, Ufuk University, Ankara, Turkey
    • ,
  • Hakan Satıroglu, M.D.

      Affiliations

    • Department of Obstetrics and Gynecology, Faculty of Medicine, Ankara University, Ankara, Turkey

Received 23 July 2009 ,Revised 23 November 2009 ,Accepted 1 December 2009.

References 

  1. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853–861
  2. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA, et al. Anti-müllerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod. 2004;10:77–83
  3. Pigny P, Cortet-Rudelli C, Decanter C, Deroubaix D, Soudan B, Duhamel A, et al. Elevated serum level of anti-müllerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab. 2003;88:5957–5962
  4. Laven JSE, Mulders AG, Visser JA, Themmen AP, De Jong FH, Fauser BCJM. Anti-müllerian hormone serum concentration in normoovulatory and anovulatory women of reproductive age. J Clin Endocrinol Metab. 2004;89:318–323
  5. Cook CL, Siow Y, Brenner AG, Fallat ME. Relationship between serum müllerian-inhibiting substance and other reproductive hormones in untreated women with polycystic ovary syndrome and normal women. Fertil Steril. 2002;77:141–146
  6. Chen MJ, Yang WS, Chen CL, wu MY, Yang YS, Ho HN. The relationship between anti-müllerian hormone, androgen and insulin resistance on the number of antral follicles in women with polycystic ovary syndrome. Hum Reprod. 2008;23:952–957
  7. Hughesdon PE. Morphology and morphogenesis of the Stein-Leventhal ovary and of so-called “hyperthecosis”. Obstet Gynecol Surv. 1982;37:59–77
  8. Stubbs SA, Hardy K, Silva-Buttkus PD, Stark J, Webber LJ, Flanagan AM, et al. Anti-müllerian hormone protein expression is reduced during development the initial stages of follicle development in human polycystic ovaries. J Clin Endocrinol Metab. 2005;90:5536–5543
  9. Webber LJ, Stubbs S, Stark J, Trew GH, Margara R, Hardy K, et al. Formation and early development of follicles in the polycystic ovary. Lancet. 2003;362:1017–1021
  10. Das M, Gillott DJ, Saridogan E, Djahanbakhch O. Anti-müllerian hormone is increased in follicular fluid from stimulated ovaries in women with polycystic ovary syndrome. Hum Reprod. 2008;23:2122–2126
  11. Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T, et al. Dynamic assays of inhibin B, anti-müllerian hormone and estradiol following FSH stimulation and ovarian ultrasonography as predictors of IVF outcome. Hum Reprod. 2005;20:3178–3183
  12. Fallat ME, Siow Y, Marra M, Cook C, Carrillo A. Müllerian-inhibiting substance in follicular fluid and serum: a comparison of patients with tubal factor infertility, polycystic ovary syndrome, and endometriosis. Fertil Steril. 1997;67:962–965
  13. La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P, et al. Anti-müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod. 2004;19:2738–2741
  14. Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum anti-müllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril. 2004;82:1323–1329
  15. Lekamge DN, Barry M, Kolo M, Lane M, Gilchrist RB, Tremellen PP. Anti-müllerian hormone as a predictor of IVF outcome. Reprod Biomed Online. 2007;14:602–610
  16. Van Rooij IA, Broekmans FJ, Hunault CC, Scheffer GJ, Eijkemans MJ, de Jong FH, et al. Use of ovarian reserve tests for the prediction of ongoing pregnancy in couples with unexplained or mild male infertility. Reprod Biomed Online. 2006;12:182–190
  17. Rotterdam ESHRE/ASRM–Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term healthy risks related to polycystic ovary syndrome. Fertil Steril. 2004;82(Suppl 3):1193–1197
  18. Balen AH, Laven JS, Tan SL, Dewailly D. Ultrasound assessment of the polycystic ovary: international consensus definitions. Hum Reprod Update. 2003;9:505–514
  19. Veeck LL. An atlas of human gametes and conceptuses: an illustrated reference for assisted reproductive technology. New York: Parthenon; 1999;
  20. Stadtmauer LA, Toma SK, Riehl RM, Talbert LM. Metformin treatment of patients with polycystic ovary syndrome undergoing in vitro fertilization improves outcomes and is associated with modulation of the insulin-like growth factors. Fertil Steril. 2001;75:505–509
  21. Hwang JL, Seow KM, Lin YH, Huang LW, Hsieh BC, Tsai YL, et al. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pretreatment for patients with polycystic ovary syndrome: a prospective randomized study. Hum Reprod. 2004;19:1993–2000
  22. Tesarik J, Junca AM, Hazout A, Aubriot FX, Nathan C, Cohen-Bacrie P, et al. Embryos with high implantation potential after intracytoplasmic sperm injection can be recognized by a simple, non-invasive examination of pronuclear morphology. Hum Reprod. 2000;15:1396–1399
  23. Fanchin R, Lozano DHM, Frydman N, Gouegon A, Clemente ND, Fryman R, et al. Anti-müllerian hormone concentrations in the follicular fluid of the preovulatory follicle are predictive of the implantation potential of the ensuing embryo obtained by in vitro fertilization. J Clin Endocrinol Metab. 2007;92:1796–1802
  24. Seifer DB, MacLaughlin DT, Christian BP, Feng B, Shelden RM. Early follicular serum anti-müllerian–inhibiting substance levels are associated with ovarian response during assisted reproductive technology cycles. Fertil Steril. 2002;77:468–471
  25. Van Rooij IA, Broekmans FJ, te Velde ER, Fauser BC, Bancsi LF, de Jong FH, et al. Serum anti-müllerian hormone levels: a novel measure of ovarian reserve. Hum Reprod. 2002;17:3065–3071
  26. Fanchin R, Schonauer LM, Righini C, Guibourdenche J, Frydman R, Taieb J. Serum anti-müllerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod. 2003;18:323–327
  27. Andersen CY, Byskow AG. Estradiol and regulation of anti-müllerian hormone, inhibin-A, and inhibin-B secretion: analysis of small antral and preovulatory human follicle fluid. J Clin Endocrinol Metab. 2006;91:4064–4069
  28. Di Clemente N, Goxe B, Remy JJ, Cate R, Josso N, Vigier B, et al. Inhibitory effect of anti-müllerian hormone upon aromatase activity and LH receptors of granulosa cells of rat and porcine immature ovaries. Endocrine. 1994;2:553–558
  29. Vigier B, Picard JY, Tran D, Legeai L, Josso N. Production of anti-müllerian hormone: another homology between Sertoli and granulosa cells. Endocrinology. 1984;114:1315–1320
  30. Artini PG, Battaglia C, D'Ambrogio G, Barreca A, Droghini F, Volpe A, et al. Relationship between human oocyte maturity, fertilization and follicular fluid growth factors. Hum Reprod. 1994;9:902–906
  31. Tarin JJ, Pellicier A. Oocyte maturation in human in vitro fertilization programmes. Ann Acad Med Sing. 1992;21:492–497
  32. Hammitt DG, Syrop CH, Van Voorhis BJ, Walker DL, Miller TM, Barud KM, et al. Prediction of nuclear maturity from coronal morphology: influence of embryologist experience. J Asist Reprod Genet. 1992;9:439–446
  33. Eppig JJ. The ovary: oogenesis. In:  Hillier SG,  Kitchener HC,  Neilson JP editor. Scientific essential of reproductive medicine. London: WB Saunders; 1996;p. 147–159
  34. Takahashi C, Fujito A, Kazuka M, Sugiyama R, Ito H, Saka K. Anti-müllerian hormone substance from follicular fluid is positively associated with success in oocyte fertilization during in vitro fertilization. Fertil Steril. 2008;89:586–591
  35. Cano F, Garcia-Velasco JA, Millet A, Remohi J, Simon C, Pellicier A. Oocyte quality in polycystic ovaries revisited: identification of a particular subgroup of women. J Assist Reprod Genet. 1997;14:254–260
  36. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC. A meta-analysis of outcomes of conventional IVF in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12:13–21
  37. Kodama H, Fukuda J, Karube H, Matsui T, Shimizu Y, Tanaka T. High incidence of embryo transfer cancellations in patients with polycystic ovarian syndrome. Hum Reprod. 1995;10:1962–1967
  38. Kovacs G, Wood C. The current status of polycystic ovary syndrome. Aust NZ J Obstet Gynaecol. 2001;41:65–68
  39. Ludwig M, Finas DF, Al-Hasani S, Diedrich K, Ortmann O. Oocyte quality and treatment outcome in intracytoplasmic sperm injection cycles of polycystic ovarian syndrome patients. Hum Reprod. 1999;14:354–358
  40. Homburg R, Berkowitz D, Levy T, Feldberg D, Ashkenazi J, Ben-Rafael Z. In vitro fertilization and embryo transfer for the treatment of infertility associated with polycystic ovary syndrome. Fertil Steril. 1993;60:858–863
  41. Fong SL, Baart EB, Martini E, Schipper I, Visser JA, Themmen AP, et al. Anti-müllerian hormone: a marker for oocyte quantity, oocyte quality and embryo quality?. Reprod Biomed Online. 2008;16:664–670
  42. Ebner T, Sommergruber M, Moser M, Shebl M, Schreier-Lechner E, Tews G. Basal level of anti-müllerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod. 2006;21:2022–2026
  43. Silberstein T, Maclaughin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, et al. Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Human Reprod. 2006;21:159–163

 C.K. has nothing to disclose. R.P. has nothing to disclose. H.S. has nothing to disclose.

PII: S0015-0282(09)04137-5

doi: 10.1016/j.fertnstert.2009.12.002

Fertility and Sterility
Volume 94, Issue 6 , Pages 2202-2207 , November 2010

Article Tools

* Image Usage & Resolution